TRENTON, N.J.--(BUSINESS WIRE)--BioNJ's Eighth Annual BioPartnering Conference, scheduled for Thursday, May 3, 2018 at The Palace at Somerset Park, Somerset, will bring together nearly 400 life sciences professionals from the Northeast to Mid-Atlantic states for a day of networking, 1:1 partnering meetings, company presentations, posters, exhibits and plenary sessions.
"We're thrilled to be partnering once again with J.P. Morgan on BioNJ's BioPartnering Conference, entitled The Evolving Marketplace New World Order: Implications on Partnering & Deal Making” said Debbie Hart, President and CEO, BioNJ. "The robust full-day syllabus is designed to foster productive partnerships, create fruitful opportunities, grow the ecosystem and bolster medical innovation. We have companies attending from 12 states -- and the list is growing every day."
Hear from industry experts on capital strategy, investor
perspectives, M&A and industry trends and expectations:
Dominic
Caruso, Executive Vice President and Chief Financial Officer,
Johnson & Johnson
Michael Griffin, Managing
Director, Investment Specialist, J.P. Morgan
Matthew Roden,
Ph.D., Head of Strategic Corporate Development & Global BD
Assessment
Bristol-Myers Squibb
Nimish Shah,
VHCP, Investment Professional, Venrock
Nishit Trivedi,
Ph.D, Director, Life Sciences and Vice President, Corporate
Strategy & Development, Emerald Asset Management
Stephen
Van Besien, Managing Director, Private Bank, J.P. Morgan
John
Whittaker, Executive Director Healthcare Investment Banking, J.P.
Morgan
Jerome Zeldis, M.D., Ph.D., CMO and President,
Clinical Research, Medical Affairs and Regulatory
Sorrento
Therapeutics
______
Discuss research collaborations with world-renowned regional
institutions:
Columbia University
Coriell
Institute for Medical Research
Hackensack Meridian Health
New
Jersey Institute of Technology
New York University
Princeton
University
Rowan University
Rutgers, The State
University of New Jersey
Tufts Medical Center
University
of Pennsylvania
The Wistar Institute
______
Hear from Presenting Companies on their emerging technologies:
Aclipse
Therapeutics, LLC
Acutive Technologies, Inc.
Advaxis,
Inc.
Apexian Pharmaceuticals Company
Azure
Biotech, Inc.
AzurRx BioPharma, Inc.
BioAegis
Therapeutics, Inc.
BioDirection, Inc.
Cancer
Genetics, Inc.
Citius Pharmaceuticals, Inc.
ContraVir
Pharmaceuticals, Inc.
Engage Therapeutics, Inc.
Grace
Therapeutics
Hemispherx BioPharma, Inc.
Immune
Pharmaceuticals
Intrommune Therapeutics
LabMinds
Matinas
BioPharma Holdings, Inc.
Mirata Pharmaceuticals
NovoPedics,
Inc.
Oncoceutics, Inc.
OncoSec Medical, Inc.
Origin,
Inc.
Photocure
PolyAurum LLC
Rafael
Pharmaceuticals, Inc.
ReadCoor, Inc.
Salix
Pharmaceuticals
Simphotek, Inc.
Skyran
Biologics, Inc.
Soligenix, Inc.
Somatix, Inc.
______
Join public and private company investors, industry executives and institution and partnering professionals for a day of collaboration, partnership and inspiration. Register now. Registration is $350 for BioNJ Members and $395 for future members. For exhibiting and sponsorship opportunities or any questions, contact Edie Esposito at 609-890-3185 or EEsposito@BioNJ.org.
Thank you to our Sponsors and Supporting Partners Amicus Therapeutics; Ashton Tweed; BIO; BioCT; Brand Institute; Bristol-Myers Squibb; Choose New Jersey; Delaware Bio; Dynamic Strategies; EisnerAmper; Fisher Scientific; FlexPro Group; Friedman LLP; Haug Partners; Invest in Ontario; Johnson & Johnson; Lab Owl; Licensing Executive Society; MassBio; Masy BioServices; McCarter & English; Merck & Co.; Merrill Corporation; New Jersey Economic Development Authority; New Jersey Health Foundation; New York BIO; Pfizer; Precision Medicine Leaders Summit; Princeton Innovation Center; RSM; RxS; Withum.
About BioNJ
BioNJ is a trade association of nearly 400 Member companies representing research-based life sciences organizations and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can't Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.
